Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
DSGN Analyst Ratings
Hold
0 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DSGN Stock 12 Month Forecast
Average Price Target
$5.00
▼(-3.10% Downside)
| Highest Price Target$5.00 | Average Price Target$5.00 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$5
Hold
-3.10%
Downside
Reiterated
08/12/25
Design Therapeutics: Hold Rating Amid Regulatory Hurdles and Financial CautionWe do note that DSGN received a clinical hold notice in the US for the Phase 1/2 RESTORE-FA study (here), which the company plans to address with clinical data and additional nonclinical data, if needed. The study will continue outside the US, and DSGN began dosing patients in June 2025. We look forward to additional updates, including clarity on when to expect a first look at FA patient data, which could drive investor interest back towards DSGN, if positive. Elsewhere in the pipeline, DSGN has initiated a Phase 2 biomarker study of DT-168 to evaluate safety, tolerability, and corneal endothelium biomarkers in Fuchs endothelial corneal dystrophy (FECD) patients who are scheduled for corneal transplant surgery.
RBC Capital
$5
Hold
-3.10%
Downside
Reiterated
08/07/25
Piper Sandler
$12
Buy
132.56%
Upside
Reiterated
05/08/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
05/01/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$5
Hold
-3.10%
Downside
Reiterated
08/12/25
Design Therapeutics: Hold Rating Amid Regulatory Hurdles and Financial CautionWe do note that DSGN received a clinical hold notice in the US for the Phase 1/2 RESTORE-FA study (here), which the company plans to address with clinical data and additional nonclinical data, if needed. The study will continue outside the US, and DSGN began dosing patients in June 2025. We look forward to additional updates, including clarity on when to expect a first look at FA patient data, which could drive investor interest back towards DSGN, if positive. Elsewhere in the pipeline, DSGN has initiated a Phase 2 biomarker study of DT-168 to evaluate safety, tolerability, and corneal endothelium biomarkers in Fuchs endothelial corneal dystrophy (FECD) patients who are scheduled for corneal transplant surgery.
RBC Capital
$5
Hold
-3.10%
Downside
Reiterated
08/07/25
Piper Sandler
$12
Buy
132.56%
Upside
Reiterated
05/08/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
05/01/25
Best Analysts Covering Design Therapeutics
1 Month
xxx
Success Rate
1/7 ratings generated profit
Average Return
-30.64%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 14.29% of your transactions generating a profit, with an average return of -30.64% per trade.
3 Months
xxx
Success Rate
2/7 ratings generated profit
Average Return
-27.39%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -27.39% per trade.
1 Year
Success Rate
1/7 ratings generated profit
Average Return
-48.14%
reiterated a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -48.14% per trade.
2 Years
xxx
Success Rate
2/7 ratings generated profit
Average Return
-43.19%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -43.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DSGN Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Aug 25
Strong Buy
0
0
1
1
1
Buy
0
0
0
0
0
Hold
5
4
8
7
9
Sell
5
6
4
1
0
Strong Sell
0
0
0
0
0
total
10
10
13
9
10
Each month's total comprises the sum of three months' worth of ratings.
DSGN Financial Forecast
DSGN Stock Forecast FAQ
What is DSGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Design Therapeutics’s 12-month average price target is 5.00.
What is DSGN’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DSGN, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DSGN a Buy, Sell or Hold?
Design Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 2 hold ratings and 0 sell ratings.
What is Design Therapeutics’s price target?
The average price target for Design Therapeutics is 5.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents -3.10% Decrease from the current price of $5.16.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents -3.10% Decrease from the current price of $5.16.
What do analysts say about Design Therapeutics?
Design Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of DSGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.